GENOME-WIDE SCREENING OF LOSS OF HETEROZYGOSITY IN HUMAN MIDGUT CARCINOID TUMORS WITH FLUORESCENT TECHNIQUERuth Mari Caroline Löllgen Vorwort891.1.1.1.2.1.3.1.4.2.102.1.2.2.2.3.2.4.3.113.1.12133.1.1.3.1.1.1.3.1.1.2.3.1.2.3.1.2.1.143.1.2.2.3.2.153.3.3.3.1.163.3.2.3.3.3.173.4.3.4.1.3.4.1.1.3.4.1.2.3.4.2.183.4.3.3.4.4.3.4.5.3.4.6.3.4.7.3.5.193.6.3.6.1.203.7.3.7.1.4.214.1.4.2.22234.3.4.4.244.5.5.5.1.255.2.5.3.6.267.278.8.1.288.2.298.3.308.4.313233614#7329.343510.363738 REFERENCES394041424344454647Abbreviations Acknowledgements49 Lebenslauf505152 Eidestattliche Erklärung53enTable of contentsHelp REFERENCES Agarwal, S. K., S. C. Guru, et al. (1999). “Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription.” Cell 96 (1): 143-52. Agarwal, S. K., M. Kester, et al. (1997). “Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states.” Hum Mol Genet 6: 1169-75. Antalis, T. M., J. A. Reeder, et al. (1998). “Down-regulation of the down-regulated in adenoma (DRA) gene correlates with colon tumor progression.” Clin Cancer Res 4 (8): 1857-63. Anthony, P. P. and R. A. Drury (1970). “Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma.” J Clin Pathol 23 (2): 110-8. Aoki, A., T. Tsukada, et al. (1997). “Multiple endocrine neoplasia type 1 presented with manic-depressive disorder: a case report with an identified MEN1 gene mutation.” Jpn J Clin Oncol 27: 419-22. Arber, N., A. I. Neugut, et al. (1997). “Molecular genetics of small bowel cancer.” Cancer Epidemiol Biomarkers Prev 6 (9): 745-8. Bakker, W. H., R. Albert, et al. (1991). “[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.” Life Sci 49 (22): 1583-91. Bartsch, D., S. A. Hahn, et al. (1999). “Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors.” Oncogene 18 (14): 2367-71. Basset, J. H., S. A. Forbes, et al. (1998). “Characterization of mutations in patients with multiple endocrine neoplasia type 1.” Am J Hum Genet 62: 232-44. Benachenhou, N., S. Guiral, et al. (1998). “High resolution deletion mapping reveals frequent allelic losses at the DNA mismatch repair loci hMLH1 and hMSH3 in non-small cell lung cancer.” Int J Cancer 77 (2): 173-80. Blanquet, V., F. Garreau, et al. (1988). “Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer.” Hum Genet 80 (3): 274-6. Bold, R. J., J. Ishizuka, et al. (1995). “Nerve growth factor as a mitogen for a pancreatic carcinoid cell line.” J Neurochem 64 (6): 2622-8. Bos, J. L., E. R. Fearon, et al. (1987). “Prevalence of ras gene mutations in human colorectal cancers.” Nature 327 (6120): 293-7. Brunsson, I., J. Fahrenkrug, et al. (1990). “On the role of vasoactive intestinal polypeptide and tachykinins in the secretory reflex elicited by chemical peritonitis in the cat small intestine.” Acta Physiol Scand 139 (1): 63-75. Bystrom, C., C. Larsson, et al. (1990). “Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors.” Proc Natl Acad Sci U S A 87 (5): 1968-72. Calender, A. (1998). “Genetic testing in multiple endocrine neoplasia and related syndromes.” Forum (Genova) 8 (2): 146-59. Carson, D. A. and A. Lois (1995). “Cancer progression and p53.” Lancet 346 (8981): 1009-11. Cavenee, W. K., T. P. Dryja, et al. (1983). “Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.” Nature 305 (5937): 779-84. Cavenee, W. K., M. F. Hansen, et al. (1985). “Genetic origin of mutations predisposing to retinoblastoma.” Science 228 (4698): 501-3. Chandrasekharappa, S. C., S. C. Guru, et al. (1997). “Positional cloning of the gene for multiple endocrine neoplasia-type 1.” Science 276 (5311): 404-7. Chaudhry, A., K. Oberg, et al. (1994). “Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system.” Anticancer Res 14: 2085-91. Chaudhry, A., V. Papanicolaou, et al. (1992). “Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system.” Cancer Res 52: 1006-12. Chu, G. and L. Mayne (1996). “Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy: do the genes explain the diseases?” Trends Genet 12 (5): 187-92. Chung, D. C., S. B. Brown, et al. (1998). “Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors.” Cancer Res 58 (16): 3706-11. D´Adda, T., S. Pizzi, et al. (2002). “Different Patterns of 11q Allelic losses in Digestive Endocrine Tumors.” Human Pathology 33 (3): 322-329. Davis, Z., C. G. Moertel, et al. (1973). “The malignant carcinoid syndrome.” Surg Gynecol Obstet 137 (4): 637-44. Debas, H. T. and S. J. Mulvihill (1994). “Neuroendocrine gut neoplasms. Important lessons from uncommon tumors.” Arch Surg 129 (9): 965-71; discussion 971-2. Debelenko, L. V., M. R. Emmert-Buck, et al. (1997a). “The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids.” Gastroenterology 113 (3): 773-81. DeLellis, R. A. (1995). “Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features.” Lab Invest 72 (5): 494-505. Eckhauser, F. E., L. C. Argenta, et al. (1981). “Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids.” Surgery 90 (4): 720-8. Eppert, K., S. W. Scherer, et al. (1996). “MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.” Cell 86 (4): 543-52. Eriksson, B., H. Arnberg, et al. (1990). “Neuroendocrine pancreatic tumours:Clinical presentation, biochemical and histopathological findings in 84 patients.” J Intern Med 228 (2): 103-13. Eriksson, B., E. Larsson, et al. (1989). “Neuroendocrine pancreatic tumors.Clinical findings in a prospective study of 84 patients.” Acta Oncol 28: 373-7. Eriksson, B., E. Larsson, et al. (1998). “Liver embolization of patients with malignant neuroendocrine gastrointestinal tumors.” Cancer 83: 2293-301. Eshleman, J. R. and S. D. Markowitz (1996). “Mismatch repair defects in human carcinogenesis.” Hum Mol Genet 5 (Spec No): 1489-94. Farid, N. R., S. Buehler, et al. (1980). “Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors.” Am J Med 69 (6): 874-80. Fearon, E. R., K. R. Cho, et al. (1990). “Identification of a chromosome 18q gene that is altered in colorectal cancers.” Science 247 (4938): 49-56. Fearon, E. R., B. C. Ekstrand, et al. (1994). “Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues.” Cold Spring Harb Symp Quant Biol 59: 637-43. Feldman, J. M. (1989). “Carcinoid tumors and the carcinoid syndrome.” Curr Probl Surg 26 (12): 835-85. Feldman, J. M. and T. M. O'Dorisio (1986). “Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.” Am J Med 81 (6B): 41-8. Fishel, R. (1998). “Mismatch repair, molecular switches, and signal transduction.” Genes Dev 12 (14): 2096-101. Fishel, R. and R. D. Kolodner (1995). “Identification of mismatch repair genes and their role in the development of cancer.” Curr Opin Genet Dev 5 (3): 382-95. Ford, J. M. and P. C. Hanawalt (1997). “Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts.” J Biol Chem 272 (44): 28073-80. Friedl, W., R. Kruse, et al. (1999). “Frequent 4-bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients.” Genes Chromosomes Cancer 25 (4): 403-6. Friedman, E., K. Sakaguchi, et al. (1989). “Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1.” N Engl J Med 321: 213-8. Funa, K., V. Papanicolaou, et al. (1990). “Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors.” Cancer Res 50 (3): 748-53. Gartel, A. L., M. S. Serfas, et al. (1996). “p21--negative regulator of the cell cycle.” Proc Soc Exp Biol Med 213 (2): 138-49. Ghimenti, C., A. Lonobile, et al. (1999). “Microsatellite instability and allelic losses in neuroendocrine tumors of the gastro-entero-pancreatic system.” Int J Oncol 15 (2): 361-6. Gobl, A. E., M. Berg, et al. (1999). “Menin represses JunD-activated transcription by a histone deacetylase- dependent mechanism.” Biochim Biophys Acta 1447 (1): 51-6. Godwin, J. D. d. (1975). “Carcinoid tumors. An analysis of 2,837 cases.” Cancer 36 (2): 560-9. Gortz, B., J. Roth, et al. (1999). “Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms.” Am J Pathol 154 (2): 429-36. Granberg, D., E. Wilander, et al. (2000). “Prognostic markers in patients with typical bronchial carcinoid tumors.” J Clin Endocrinol Metab 85: 3425-3430. Greenberg, R. S., D. A. Baumgarten, et al. (1987). “Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors.” Cancer 60 (10): 2476-83. Grimelius, L. and E. Wilander (1980). “Silver stains in the study of endocrine cells of the gut and pancreas.” Invest Cell Pathol 3 (1): 3-12. Guo, Z., Q. Li, et al. (2000). “Clonality analysis of multifocal carcinoid tumours of the small intestine by X-chromosome inactivation analysis.” J Pathol 190 (1): 76-9. Heppner, C., M. Reincke, et al. (1999). “MEN1 gene analysis in sporadic adrenocortical neoplasms.” J Clin Endocrinol Metab 84 (1): 216-9. Hessman, O., D. Lindberg, et al. (1999). “Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1- associated pancreatic endocrine tumors.” Genes Chromosomes Cancer 26 (3): 258-64. Hessman, O., D. Lindberg, et al. (1998). “Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas.” Cancer Res 58 (3): 377-9. Hibi, K., T. Takahashi, et al. (1992). “Three distinct regions involved in 3p deletion in human lung cancer.” Oncogene 7 (3): 445-9. Hilgers, W., J. J. Song, et al. (2000). “Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers.” Genes Chromosomes Cancer 27 (4): 353-7. Howe, J. R., S. Roth, et al. (1998). “Mutations in the Smad4/DPC4 gene in juvenile polyposis.” Science May 280: 1086-8. Huang, S. C., Z. Zhuang, et al. (1999). “Nuclear/cytoplasmic localization of the multiple endocrine neoplasia type 1 gene product, menin.” Lab Invest 79 (3): 301-10. Imam, H., B. Eriksson, et al. (1997). “Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin anlogues.” Acta Oncol 36: 607-14. Jakobovitz, O., D. Nass, et al. (1996). “Carcinoid tumors frequently display genetic abnormalities involving chromosome 11 [see comments].” J Clin Endocrinol Metab 81 (9): 3164-7. Janson, E. T., L. Holmberg, et al. (1997). “Carcinoid tumors:analysis of prognostic factors and survival in 301 patients from a referral center.” Ann Oncol 8: 685-90. July, L. V., K. A. Northcott, et al. (1999). “Coexisting carcinoid tumors in familial adenomatous polyposis- associated upper intestinal adenomas.” Am J Gastroenterol 94 (4): 1091-4. Kinzler, K. W., M. C. Nilbert, et al. (1991). “Identification of FAP locus genes from chromosome 5q21.” Science 253 (5020): 661-5. Kjellman, M., L. Roshani, et al. (1999). “Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16.” J Clin Endocrinol Metab 84 (2): 730-5. Kloppel, G., E. Solcia, et al. (1999). “Classification of neuroendocrine tumours.” Ital J Gastroenterol Hepatol 31 (Suppl 2): S 111-6. Knudson, A. G., Jr. (1978). “Retinoblastoma: a prototypic hereditary neoplasm.” Semin Oncol 5 (1): 57-60. Knudson, A. G., Jr., N. Di Ferrante, et al. (1971). “Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis.” Proc Natl Acad Sci U S A 68 (8): 1738-41. Kolodner, R. (1996). “Biochemistry and genetics of eukaryotic mismatch repair.” Genes Dev 10 (12): 1433-42. Kong, X. T., S. H. Choi, et al. (1997). “Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.” Cancer Res 57 (17): 3772-8. Krejs, G. J., L. Orci, et al. (1979). “Somatostatinoma syndrome. Biochemical, morphologic and clinical features.” N Engl J Med 301 (6): 285-92. Kytola, S., B. Nord, et al. (2002). “Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.” Genes Chromosomes Cancer 34 (3): 325-332. La Rosa, S., F. Sessa, et al. (1996). “Prognostic criteria in non functioning pancreatic endocrine tumours.” Virchow Arch 429: 323-333. Lambert, W. C., H. R. Kuo, et al. (1995). “Xeroderma pigmentosum.” Dermatol Clin 13 (1): 169-209. Lamberts, R. and M. Gregor (1999). “Multiple endocrine neoplasia Type I. Diagnosis and therapy in a case with classical family history (published erratum appears in Med Klin 1999 Sep 15;94(9):521).” Med Klin 94 (8): 447-52. Larsson, C., B. Skogseid, et al. (1988). “Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma.” Nature 332 (6159): 85-7. Ledgerwood, E. C., J. S. Pober, et al. (1999). “Recent advances in the molecular basis of TNF signal transduction.” Lab Invest 79 (9): 1041-50. Lembeck, F. (1953). “5-Hydroxytryptamine in a carcinoid tumor.” Nature 172: 910-11. Lemmens, I., W. J. Van de Ven, et al. (1997). “Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1.” Hum Mol Genet 6 (7): 1177-83. Liu, B., R. E. Parsons, et al. (1994). “hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds.” Cancer Res 54 (17): 4590-4. Lucas, K. J. and J. M. Feldman (1986). “Flushing in the carcinoid syndrome and plasma kallikrein.” Cancer 58 (10): 2290-3. Lundin, L. (1991). “Carcinoid heart disease. A cardiologist's viewpoint.” Acta Oncol 30 (4): 499-502. Makridis, C., A. Ekbom, et al. (1997). “Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors.” Surgery 122 (6): 1075-82. Makridis, C., J. Rastad, et al. (1996). “Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors.” World J Surg 20 (7): 900-6; discussion 907. Mallette, L. E. (1994). “Management of hyperparathyroidism in the multiple endocrine neoplasia syndromes and other familial endocrinopathies.” Endocrinol Metab Clin North Am 23 (1): 19-36. Mani, S., I. M. Modlin, et al. (1994). “Carcinoids of the rectum.” J Am Coll Surg 179 (2): 231-48. Marshall, C. J. (1991). “Tumor suppressor genes.” Cell 64 (2): 313-26. Martin, S. J. and D. R. Green (1995). “Protease activation during apoptosis: death by a thousand cuts?” Cell 82 (3): 349-52. Marx, S. J., S. K. Agarwal, et al. (1998). “Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1).” J Intern Med 243 (6): 447-53. Marx, S. J., S. K. Agarwal, et al. (1999). “Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.” Recent Prog Horm Res 54: 397-438. Mayr, B., S. Apenberg, et al. (1997). “Menin mutations in patients with multiple endocrine neoplasia type 1.” Eur J Endocrinol 137: 684-7. McCutcheon, I. E. (1994). “Management of individual tumor syndromes. Pituitary neoplasia.” Endocrinol Metab Clin North Am 23 (1): 37-51. McDermott, E. W., B. Guduric, et al. (1994). “Prognostic variables in patients with gastrointestinal carcinoid tumours.” Br J Surg 81 (7): 1007-9. Metz, D. C. (1995). “Multiple endocrine neoplasia type I.” Semin Gastrointest Dis 6 (2): 56-66. Moertel, C., W. Sauer, et al. (1961). “Life history of the carcinoid tumor of the small intestine.” Cancer 14: 901-12. Moertel, C. G. (1987). “Karnofsky memorial lecture. An odyssey in the land of small tumors.” J Clin Oncol 5 (10): 1502-22. Moesta, K. T. and P. Schlag (1990). “Proposal for a new carcinoid tumour staging system based on tumour tissue infiltration and primary metastasis; a prospective multicentre carcinoid tumour evaluation study. West German Surgical Oncologists' Group.” Eur J Surg Oncol 16 (4): 280-8. Nilsson, O., B. Wangberg, et al. (1995). “Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours.” Int J Cancer 60 (5): 645-51. Nilsson, O., B. Wangberg, et al. (1993). “Growth factors and carcinoid tumors.” Acta Oncol 32: 115-24. Nord, B., C. Larsson, et al. (1999). “Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in the MEN1 gene.” Genes Chromosomes Cancer 26 (1): 35-9. Norheim, I., E. Theodorsson-Norheim, et al. (1986). “Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.” J Clin Endocrinol Metab 63 (3): 605-12. Oberg, K. (1996). “Neuroendocrine gastrointestinal tumours.” Ann Oncol 7 (5): 453-63. Oberg, K., B. Eriksson, et al. (1994). “Interferones alone or in combination with chemotherapy ot other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.” Digestion 55: 64-9. Oberg, K., I. Norheim, et al. (1989). “Treatment of malignant carcinoid tumors:a randomized controlled study of streptozocin plus 5-FU and human leucocyte interferone.” Eur J Cancer Clin Oncol 25 :1475-1479. Olufemi, S. E., J. S. Green, et al. (1998). “Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland.” Hum Mutat 11: 264-9. Panariello, L., M. I. Scarano, et al. (1998). “hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds. Mutations in brief no. 182. Online.” Hum Mutat 12 (3): 216-7. Papadimitrakopoulou, V. A., Y. Oh, et al. (1998). “Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer.” Clin Cancer Res 4 (3): 539-44. Pearse, A. G. (1974). “The APUD cell concept and its implications in pathology.” Pathol Annu 9 (0): 27-41. Pearson, C. and P. Fitzgerald (1949). “Carcinoid tumors - a re-emphasis of their malignant nature. Review of 140 cases.” Cancer 2: 1005-26. Pelosi, G., E. Bresaola, et al. (1996). “Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables.” Hum Pathol 27 (11): 1124-34. Pipeleers-Marichal, M., C. Donow, et al. (1993). “Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I.” World J Surg 17 (4): 481-8. Plöckinger, U. and B. Wiedenmann (2000). Systemic therapy for metastatic or residual extrapancreatic neuroendocrine tumors.

Philadelphia,

Lippincott, Williams and Wilkins. Ramnani, D. M., Wistuba, II, et al. (1999). “K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix.” Cancer 86 (1): 14-21. Regoli, D. and F. Nantel (1991). “Pharmacology of neurokinin receptors.” Biopolymers 31 (6): 777-83. Reubi, J. C., L. K. Kvols, et al. (1990). “Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.” Cancer Res 50 (18): 5969-77. Rindi, G., C. Bordi, et al. (1996). “Gastric carcinoids and Neuroendocrine Carcinomas: Pathogenesis, Pathology, and Behaviour.” World J Surg 20: 168-172. Rindi, G., C. Capella, et al. (2000). “Introduction to a revised clinico-pathological classification of neuroendocrine tumors of the gastroenteropancreatic tract.” QJ Nucl Med 44: 13-21. Sanders, R. and H. Axtel (1964). “Carcinoids of the gastrointestinal tract.” Surg Gynecol Obstet 11: 369-80. Schmutte, C. and P. A. Jones (1998). “Involvement of DNA methylation in human carcinogenesis.” Biol Chem 379 (4-5): 377-88. Schutte, M., R. H. Hruban, et al. (1996). “DPC4 gene in various tumor types.” Cancer Res 56 (11): 2527-30. Sjokvist, A., I. Brunsson, et al. (1993). “On the involvement of tachykinin neurons in the secretory nervous reflex elicited by cholera toxin in the small intestine.” Acta Physiol Skand 148: 387-92. Skogseid, B. (2001). “Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids.” World J Surg 25: 700-703. Skogseid, B., B. Eriksson, et al. (1991). “Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds.” J Clin Endocrinol Metab 73 (2): 281-7. Skogseid, B., J. Rastad, et al. (1995). “Adrenal lesions in multiple endocrine neoplasia type 1.” Surgery 118: 1077-82. Smith, J. R., J. D. Carpten, et al. (1995). “Approach to genotyping errors caused by nontemplated nucleotide addition by Taq DNA polymerase.” Genome Res 5 (3): 312-7. Stacpoole, P. W. (1981). “The glucagonoma syndrome: clinical features, diagnosis, and treatment.” Endocr Rev 2 (3): 347-61. Stridsberg, M., K. Oberg, et al. (1995). “Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.” J Endocrinol 144 (1): 49-59. Strodel, W. E., G. Talpos, et al. (1983). “Surgical therapy for small-bowel carcinoid tumors.” Arch Surg 118 (4): 391-7. Sun, Y., A. Hildesheim, et al. (1995). “No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.” Oncogene 10: 785-8. Takagi, Y., H. Kohmura, et al. (1996). “Somatic alterations of the DPC4 gene in human colorectal cancers in vivo [see comments].” Gastroenterology 111 (5): 1369-72. Tanaka, C., T. Kimura, et al. (1998). “Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN1 gene in sporadic pituitary adenomas [see comments].” J Clin Endocrinol Metab 83 (8): 2631-4. Thakker, R. V., P. Bouloux, et al. (1989). “Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11.” N Engl J Med 321 (4): 218-24. The European Consortium on MEN1. (1997). “Identification of the multiple endocrine neoplasia type 1 (MEN1) gene.The European Consortium on MEN 1.” Hum Mol Genet 6: 1177-83. Thompson, G. B., J. A. van Heerden, et al. (1985). “Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis.” Surgery 98 (6): 1054-63. Tiensuu Janson, E., J. Westlin, et al. (1994). “(111IN-DTPA-D-Phe) octreotide scintigraphy in patients with carcinoid tumours:the predictive value for somatostatin analogue treatment.” Eur J Endocrinol 131: 577-81. Tiensuu Janson, E. M. and K. E. Oberg (1996). “Carcinoid tumours.” Baillieres Clin Gastroenterol 10 (4): 589-601. Toliat, M. R., W. Berger, et al. (1997). “Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system [letter].” Lancet 350 (9086): 1223. Uchida, K., M. Nagatake, et al. (1996). “Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers.” Cancer Res 56 (24): 5583-5. Van Hazel, G., J. Rubin, et al. (1983). “Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine.” Cancer Treat Rep 67: 583-585. Vogelstein, B. and K. Kinzler (1993). “The multistep nature of cancer.” Trends genet 9: 138-41. Wang, E. H., S. A. Ebrahimi, et al. (1998). “Mutation of the MENIN gene in sporadic pancreatic endocrine tumors.” Cancer Res 58 (19): 4417-20. Weckstrom, P., A. Hedrum, et al. (1996). “Midgut Carcinoids and Solid Carcinomas of the Intestine:Differences in Endocrine Markers and p53 Mutations.” Endocrine pathology 7: 273-279. Weinberg, R. A. (1991). “Tumor suppressor genes.” Science 254 (5035): 1138-46. Weitzman, J. B. and M. Yaniv (1999). “Rebuilding the road to cancer [news; comment].” Nature 400 (6743): 401-2. Wermer, P. (1963). “Endocrine adenomatosis and peptic ulcer in a large kindred:inherited mutiple tumors and mosaic pleiotropism in man.” Am J Med 35: 205-12. Wessels, F. J. and S. R. Schell (2001). “Radiofrequency Ablation Treatment of Refractory Carcinoid Hepatic Metastases.” J Surg Res 95: 8-12. Wilander, E. and L. Grimelius (1993). “Identification, characterization and classification of endocrine tumours.” Zentralbl Pathol 139 (2): 95-100. Wilander, E., M. Lundqvist, et al. (1989). “Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects.” Prog Histochem Cytochem 19 (2): 1-88. Wilentz, R. E., G. H. Su, et al. (2000). “Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.” Am J Pathol 156 (1): 37-43. Williams, E. and J. Azzopardi (1960). “Tumours of the lung and the carcinoid syndrome.” Thorax 15: 30-36. Williams, E. and M. Sandler (1963). “The classification of carcinoid tumors.” Lancet 1 : 238. Younes, N., N. Fulton, et al. (1997). “The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors.” Cancer 79 (9): 1804-8. Zhao, J., R. R. de Krijger, et al. (2000). “Genomic Alterations in Well-Differentiated Gastrointestinal and Bronchial Neuroendocrine Tumors (Carcinoids).” Am J Pathol 157: 1431-38. Zhuang, Z., A. O. Vortmeyer, et al. (1997). “Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas.” Cancer Res 57 (21): 4682-6. Zollinger, R. M., E. C. Ellison, et al. (1980). “Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five-year appraisal.” Ann Surg 192 (3): 422-30.